Contact
 

Daily Dose of HIV Drug Reduces Risk of HIV Infection - NIAID Statement

The National Institutes of Health (NIH) issued a statement on the iPrEx study results, http://www.niaid.nih.gov/news/newsreleases/2010/Pages/iPrEx.aspx.   The statement quotes Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health who said, “We now have strong evidence that pre-exposure prophylaxis with an antiretroviral drug, a strategy widely referred to as PrEP, can reduce the risk of HIV acquisition among men who have sex with men, a segment of the population disproportionately affected by HIV/AIDS.”

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account